Insights into RNA [N.sup.6]-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies

The incidence of glucose and lipid metabolism diseases, including type 2 diabetes, obesity, metabolic syndrome, and nonalcoholic fatty liver disease, is rising, which places an enormous burden on people around the world. However, the mechanism behind these disorders remains incompletely understood. [N.sup.6]-methyladenosine ([m.sup.6]A) is 1 type of posttranscriptional RNA modification, and research has shown that it plays a crucial role in several metabolic diseases. [m.sup.6]A methylation is reversibly and dynamically regulated by methyltransferases (writers), demethylases (erasers), and [m.sup.6]A binding proteins (readers). Dysregulation of RNA [m.sup.6]A modification is related to different metabolic processes. Targeting RNA [m.sup.6]A methylation is a potential treatment strategy for these chronic metabolic diseases. This review discusses studies on RNA [m.sup.6]A modification in metabolic diseases and existing therapeutic drugs, with the aim of providing a concise perspective on its potential applications in managing metabolic disorders. Key Words: glucose and lipid metabolism, RNA [N.sup.6]-methyladenosine, metabolic disorders, intervention, epigenetics